Cerus Corporation (CERS) - Total Assets
Based on the latest financial reports, Cerus Corporation (CERS) holds total assets worth $222.91 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cerus Corporation cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cerus Corporation - Total Assets Trend (1997–2025)
This chart illustrates how Cerus Corporation's total assets have evolved over time, based on quarterly financial data. Check CERS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Cerus Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Cerus Corporation's total assets of $222.91 Million consist of 78.6% current assets and 21.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.0% |
| Accounts Receivable | $30.37 Million | 13.7% |
| Inventory | $56.10 Million | 25.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.32 Million | 0.6% |
Asset Composition Trend (1997–2025)
This chart illustrates how Cerus Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Cerus Corporation worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cerus Corporation's current assets represent 78.6% of total assets in 2025, a decrease from 96.0% in 1997.
- Cash Position: Cash and equivalents constituted 9.0% of total assets in 2025, down from 42.5% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is inventory at 25.3% of total assets.
Cerus Corporation Competitors by Total Assets
Key competitors of Cerus Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Cerus Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 2.32 | 2.82 |
| Quick Ratio | 1.06 | 1.63 | 2.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $67.96 Million | $91.83 Million | $119.78 Million |
Cerus Corporation - Advanced Valuation Insights
This section examines the relationship between Cerus Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.77 |
| Latest Market Cap to Assets Ratio | 2.32 |
| Asset Growth Rate (YoY) | 10.4% |
| Total Assets | $221.86 Million |
| Market Capitalization | $514.95 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cerus Corporation's assets at a significant premium (2.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Cerus Corporation's assets grew by 10.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cerus Corporation (1997–2025)
The table below shows the annual total assets of Cerus Corporation from 1997 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $221.86 Million | +10.42% |
| 2024-12-31 | $200.92 Million | +1.60% |
| 2023-12-31 | $197.75 Million | -9.33% |
| 2022-12-31 | $218.09 Million | -8.17% |
| 2021-12-31 | $237.50 Million | +7.26% |
| 2020-12-31 | $221.41 Million | +33.76% |
| 2019-12-31 | $165.53 Million | +1.27% |
| 2018-12-31 | $163.46 Million | +66.38% |
| 2017-12-31 | $98.24 Million | -5.06% |
| 2016-12-31 | $103.48 Million | -25.81% |
| 2015-12-31 | $139.47 Million | +70.56% |
| 2014-12-31 | $81.77 Million | -1.93% |
| 2013-12-31 | $83.38 Million | +70.45% |
| 2012-12-31 | $48.92 Million | +7.83% |
| 2011-12-31 | $45.37 Million | -5.81% |
| 2010-12-31 | $48.17 Million | +39.65% |
| 2009-12-31 | $34.49 Million | -27.14% |
| 2008-12-31 | $47.34 Million | -39.47% |
| 2007-12-31 | $78.21 Million | -32.47% |
| 2006-12-31 | $115.82 Million | +97.44% |
| 2005-12-31 | $58.66 Million | -42.53% |
| 2004-12-31 | $102.08 Million | -13.83% |
| 2003-12-31 | $118.46 Million | +62.40% |
| 2002-12-31 | $72.95 Million | -43.13% |
| 2001-12-31 | $128.26 Million | +36.21% |
| 2000-12-31 | $94.16 Million | +125.27% |
| 1999-12-31 | $41.80 Million | +100.00% |
| 1998-12-31 | $20.90 Million | -23.44% |
| 1997-12-31 | $27.30 Million | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more